Abstract
Chronic kidney disease and especially end-stage renal disease (ESRD) are regularly associated with profound disturbances in the mineral metabolism characterized by secondary hyperparathyroidism (SHPT), hyperphosphatemia, hypercalcemia, elevated calcium-phosphorus product and renal osteodystrophy. These metabolic changes are either the result of the disease itself or due to toxicity from current therapeutic options. There is growing evidence that besides the classical cardiovascular risk factors, non-traditional uremia-specific risk factors, including abnormal mineral metabolism and SHPT, play a key role in the excessively increased cardiovascular mortality and morbidity in these patients. Calcimimetics represent an innovative new therapeutic compound in the treatment of SHPT, acting as allosteric activators of the calcium-sensing receptor. In this review we will discuss the consequences of SHPT in ESRD patients on vascular calcification, its impact on cardiovascular morbidity and mortality and the potential role of calcimimetics in preventing the cardiovascular consequences of SHPT.
Keywords: Calcimimetics, cinacalcet, secondary hyperparathyroidism, vascular calcification, cardiovascular disease, endstage renal disease (ESRD)
Current Drug Therapy
Title: Consequences of Secondary Hyperparathyroidism on Vascular Calcification and Cardiovascular Mortality: Potential Benefit of Calcimimetics
Volume: 1 Issue: 2
Author(s): Emanuel Zitt and Alexander R. Rosenkranz
Affiliation:
Keywords: Calcimimetics, cinacalcet, secondary hyperparathyroidism, vascular calcification, cardiovascular disease, endstage renal disease (ESRD)
Abstract: Chronic kidney disease and especially end-stage renal disease (ESRD) are regularly associated with profound disturbances in the mineral metabolism characterized by secondary hyperparathyroidism (SHPT), hyperphosphatemia, hypercalcemia, elevated calcium-phosphorus product and renal osteodystrophy. These metabolic changes are either the result of the disease itself or due to toxicity from current therapeutic options. There is growing evidence that besides the classical cardiovascular risk factors, non-traditional uremia-specific risk factors, including abnormal mineral metabolism and SHPT, play a key role in the excessively increased cardiovascular mortality and morbidity in these patients. Calcimimetics represent an innovative new therapeutic compound in the treatment of SHPT, acting as allosteric activators of the calcium-sensing receptor. In this review we will discuss the consequences of SHPT in ESRD patients on vascular calcification, its impact on cardiovascular morbidity and mortality and the potential role of calcimimetics in preventing the cardiovascular consequences of SHPT.
Export Options
About this article
Cite this article as:
Zitt Emanuel and Rosenkranz R. Alexander, Consequences of Secondary Hyperparathyroidism on Vascular Calcification and Cardiovascular Mortality: Potential Benefit of Calcimimetics, Current Drug Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157488506776931012
DOI https://dx.doi.org/10.2174/157488506776931012 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy
Current Drug Discovery Technologies Algorithms and Criteria for Transcatheter Aortic Valve Replacement Patient Selection: Current Status and Future Trends
Current Pharmaceutical Design Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond
Current Pharmaceutical Design Rheumatoid Arthritis: Cardiovascular Manifestations, Pathogenesis, and Therapy
Current Pharmaceutical Design Ischemic Colitis: Current Diagnosis and Treatment
Current Drug Targets Atherosclerosis - New Targets and Therapeutics
Current Medicinal Chemistry - Cardiovascular & Hematological Agents An Increasing Incidence of Treatment Resistance in Hypertension?
Current Drug Therapy Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) The Effects of Placental Corticotrophin Releasing Hormone on the Physiology and Psychology of the Pregnant Woman
Current Women`s Health Reviews Is the Carotid Plaque Rupture a Pivotal Event in Stroke Pathogenesis? Update on the Role of the Intraplaque Inflammatory Processes
Current Vascular Pharmacology Pathogenic Bacterial Proteins and their Anti-Inflammatory Effects in the Eukaryotic Host
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Rho Kinase: An Important Mediator of Atherosclerosis and Vascular Disease
Current Pharmaceutical Design Hypertension in Diabetes: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Prognostic Role of Sub-Clinical Hypothyroidism in Chronic Heart Failure Outpatients
Current Pharmaceutical Design Biomarkers in Amyotrophic Lateral Sclerosis: Is There A Neurovascular Pathway?
Current Neurovascular Research Acute Passivation of Vulnerable Plaques with Wild-Type Apolipoprotein A-I in ApoE-Deficient Mice
Vascular Disease Prevention (Discontinued) p38 Mitogen-Activated Protein Kinase: A Critical Node Linking Insulin Resistance and Cardiovascular Diseases in Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Biomarkers of Subclinical Atherosclerosis and Natural Products as Complementary Alternative Medicine
Current Pharmaceutical Design Rheumatoid Arthritis: Conjugating Basics with Drug Delivery
Current Rheumatology Reviews Bariatric Surgery and it Effects on the Respiratory System
Current Respiratory Medicine Reviews